Scholarlink

Purpose/Objective(s) <p>Data describing the safety/efficacy of targeted therapies in combination with stereotactic radiotherapy (SRS/SRT) for brain metastases are limited. We leverage a bicentric cohort to evaluate rates of intracranial failure and radiation necrosis in patients receiving targeted therapy and SRS.</p> Materials/Methods <p>Patients with intact brain metastases at two institutions treated with SRS/SRT and concurrent central nervous system (CNS)-active targeted therapy were identified. Concurrent targeted therapy was defined as receipt of targeted therapy starting before and continuing through receipt of radiation therapy, except for a brief washout interval of 3–7 days. Patients were followed for a minimum of 3 months after SRS/SRT with brain MRI. Kaplan-Meier analysis was performed to evaluate overall survival and cumulative rates of symptomatic radiation necrosis (sRN). Variables associated with radiation necrosis on univariable analysis (<i>p</i> &lt; 0.2) were included in a multivariable logistic regression model for adjusted analysis.</p> Results <p>The study included 93 patients with 306 metastases, and median follow-up was 17 months. The overall rate of sRN per-metastasis and per-patient was 16/306 (5%) and 13/93 (13%), respectively. Symptomatic RN occurred in 6/28 (21%) of patients exposed to anti-HER2 agents overall and in 3/15 (20%) of those exposed to anti-HER2 antibody-drug conjugate agents (ADCs). Anti-HER2 demonstrated a trend toward significance (<i>p</i> = 0.107) and met the threshold for inclusion in the multivariable analysis. On adjusted analysis, exposure to anti-HER2 therapy was associated with increased odds of sRN, but this was non-significant (odds ratio 2.49, 95% CI[0.66–9.41], <i>p</i> = 0.180). Median overall survival for the cohort was 27.4 months with median intracranial progression-free survival of 12 months.</p> Conclusions <p>Patients treated with a combination of SRS/SRT and targeted therapy demonstrated a median of 12 months of intracranial control with limited radiation necrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis

  • 期刊论文

  • 发表日期：

    2026年2月9日

查看全文
  • Ethan M. Steele,
  • Jacob T. Hall,
  • Kevin Lui,
  • Rami Darawsheh,
  • John W. Shumway,
  • Lisa A. Carey,
  • Katherine E. Reeder-Hayes,
  • Carrie B. Lee,
  • Stergios J. Moschos,
  • Frances A. Collichio,
  • Soma Sengupta,
  • Dominique M. Higgins,
  • Rekha T. Chaudhary,
  • Lalanthica V. Yogendran,
  • Timothy D. Struve,
  • Ralph E. Vatner,
  • Luke E. Pater,
  • John C. Breneman,
  • Norberto O. Andaluz,
  • Jonathan A. Forbes,
  • Gaorav P. Gupta,
  • Ashley A. Weiner,
  • Kyle Wang,
  • Colette J. Shen

摘要

Purpose/Objective(s)

Data describing the safety/efficacy of targeted therapies in combination with stereotactic radiotherapy (SRS/SRT) for brain metastases are limited. We leverage a bicentric cohort to evaluate rates of intracranial failure and radiation necrosis in patients receiving targeted therapy and SRS.

Materials/Methods

Patients with intact brain metastases at two institutions treated with SRS/SRT and concurrent central nervous system (CNS)-active targeted therapy were identified. Concurrent targeted therapy was defined as receipt of targeted therapy starting before and continuing through receipt of radiation therapy, except for a brief washout interval of 3–7 days. Patients were followed for a minimum of 3 months after SRS/SRT with brain MRI. Kaplan-Meier analysis was performed to evaluate overall survival and cumulative rates of symptomatic radiation necrosis (sRN). Variables associated with radiation necrosis on univariable analysis (p < 0.2) were included in a multivariable logistic regression model for adjusted analysis.

Results

The study included 93 patients with 306 metastases, and median follow-up was 17 months. The overall rate of sRN per-metastasis and per-patient was 16/306 (5%) and 13/93 (13%), respectively. Symptomatic RN occurred in 6/28 (21%) of patients exposed to anti-HER2 agents overall and in 3/15 (20%) of those exposed to anti-HER2 antibody-drug conjugate agents (ADCs). Anti-HER2 demonstrated a trend toward significance (p = 0.107) and met the threshold for inclusion in the multivariable analysis. On adjusted analysis, exposure to anti-HER2 therapy was associated with increased odds of sRN, but this was non-significant (odds ratio 2.49, 95% CI[0.66–9.41], p = 0.180). Median overall survival for the cohort was 27.4 months with median intracranial progression-free survival of 12 months.

Conclusions

Patients treated with a combination of SRS/SRT and targeted therapy demonstrated a median of 12 months of intracranial control with limited radiation necrosis.